Goldman Sachs
PLX icon

Goldman Sachs’s Protalix BioTherapeutics PLX Stock Holding History

Goldman Sachs’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$545K Sell
251,345
-11,464
-4% -$28.4K ﹤0.01% 5549
2025
Q4 		$473K Buy
262,809
+111,980
+74% +$229K ﹤0.01% 5629
2025
Q3 		$335K Buy
150,829
+48,651
+48% +$79.2K ﹤0.01% 5701
2025
Q2 		$151K Sell
102,178
-187,283
-65% -$383K ﹤0.01% 5736
2025
Q1 		$741K Buy
289,461
+239,751
+482% +$573K ﹤0.01% 4923
2024
Q4 		$93.5K Sell
49,710
-531
-1% -$751 ﹤0.01% 5775
2024
Q3 		$51.2K Sell
50,241
-411,717
-89% -$433K ﹤0.01% 5630
2024
Q2 		$540K Buy
461,958
+369,534
+400% +$437K ﹤0.01% 4787
2024
Q1 		$116K Sell
92,424
-12,052
-12% -$18K ﹤0.01% 5219
2023
Q4 		$186K Sell
104,476
-3,319
-3% -$5.16K ﹤0.01% 5176
2023
Q3 		$179K Buy
107,795
+57,601
+115% +$103K ﹤0.01% 5067
2023
Q2 		$100K Buy
+50,194
New +$120K ﹤0.01% 5355
2018
Q3 		– Sell
-2,845
Closed -$12K – 5746
2018
Q2 		$12K Buy
2,845
+1
+0% +$4 ﹤0.01% 5532
2018
Q1 		$15K Sell
2,844
-1
-0% -$7 ﹤0.01% 5708
2017
Q4 		$19K Buy
2,845
+1
+0% +$7 ﹤0.01% 6121
2017
Q3 		$16K Buy
+2,844
New +$18.2K ﹤0.01% 6458
2017
Q1 		– Sell
-4,062
Closed -$18K – 6950
2016
Q4 		$18K Buy
4,062
+8
+0.2% +$36 ﹤0.01% 6670
2016
Q3 		$23K Hold
4,054
– – ﹤0.01% 6714
2016
Q2 		$26K Hold
4,054
– – ﹤0.01% 6632
2016
Q1 		$34K Sell
4,054
-3,643
-47% -$31.2K ﹤0.01% 6582
2015
Q4 		$79K Buy
7,697
+6,432
+508% +$65.4K ﹤0.01% 6302
2015
Q3 		$15K Buy
+1,265
New +$20.1K ﹤0.01% 7089
2014
Q4 		– Sell
-2,835
Closed -$69K – 7272
2014
Q3 		$69K Sell
2,835
-4,099
-59% -$118K ﹤0.01% 6735
2014
Q2 		$253K Buy
6,934
+4,090
+144% +$165K ﹤0.01% 6014
2014
Q1 		$130K Sell
2,844
-30
-1% -$1.4K ﹤0.01% 6300
2013
Q4 		$112K Sell
2,874
-3,172
-52% -$134K ﹤0.01% 6234
2013
Q3 		$274K Buy
6,046
+2,005
+50% +$103K ﹤0.01% 5632
2013
Q2 		$198K Buy
+4,041
New +$214K ﹤0.01% 5590

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Goldman Sachs's PLX Position: Q1 2026 in Review

Goldman Sachs reduced its Protalix BioTherapeutics (PLX) stake by 4.4% in Q1 2026, selling an estimated $28.4K and leaving 251,345 shares worth $545K. The position accounts for ﹤0.01% of the portfolio, ranked #5549.

Goldman Sachs first reported a position in PLX in Q2 2013 and has held it in 28 quarters since. The position peaked at $741K in Q1 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Goldman Sachs held 251,345 shares of Protalix BioTherapeutics worth $545K as of Q1 2026.
  • Goldman Sachs sold 11,464 Protalix BioTherapeutics shares in Q1 2026, an estimated $28.4K.
  • Protalix BioTherapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5549 holding.
  • Goldman Sachs first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 28 quarters since.
  • Goldman Sachs's Protalix BioTherapeutics position peaked at $741K in Q1 2025.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.